Welcome back!
Lopinavir was developed by Abbott in an attempt to improve on the AIDS resistance and serum protein-binding properties of the company’s earlier protease inhibitor, ritonavir. Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4. Abbott decided to employ a stretegy of co administering lopiavir with doses of rionavir and lopinavir is then marketed as a formulation containing ritonavir. Its the first multi drug capsule to have a drug not available individually.
Lopinavir/Ritonavir was approved for use by the FDA on September 15, 2000. Its patent will expire in the US on June 26, 2016.
Abbott Laboratories was one of the earliest users of the Advanced Photon Source, a national synchrotron-radiation light source at Argonne National Laboratory. An early research project undertaken at Advanced Photon Source was HIV. Using X-ray crystallography, researchers found the points of attack of the HIV protease inhibitors – agents that block the breakdown of proteins. PI’s help stop HIV from making copies of itself by stopping the last step in the process when the virus attempts to replicate and out of that discovery came the drug kaletra.
Abbott Laboratories was one of the earliest users of the Advanced Photon Source, a national synchrotron-radiation light source at Argonne National Laboratory. An early research project undertaken at Advanced Photon Source was HIV. Using x ray crystallography, researchers located the points of attack of HIV protease inhibitors, medication that block the breakdown of proteins. Protease inhibitors stop HIV from making new copies of itself by blocking the last step in the process, when the virus attempts to replicate – and out of that discovery came the drug kaletra.